Corante

About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
Kilomentor
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
ChemBark
Realizations in Biostatistics
Chemjobber
Pharmalot
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Business|Bytes|Genes|Molecules
Eye on FDA
Chemical Forums
Depth-First
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net


Medical Blogs
DB's Medical Rants
Science-Based Medicine
GruntDoc
Respectful Insolence
Diabetes Mine


Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem


Politics / Current Events
Virginia Postrel
Instapundit
Belmont Club
Mickey Kaus


Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Waiting for the FDA | Main | Can Med-Chem Help With Bird Flu? »

February 20, 2005

COX-2 Aftermath

Email This Entry

Posted by Derek

Overall, I found the conclusionsn of the FDA's COX-2 committee quite reasonable (and not too far from what I predicted during the day on Friday.) Perhaps their actions will calm things down a bit. After all, they had the chance to bay at the moon, yank everything off the market and call for heads on pikes. But they ended up saying (I'm paraphrasing just a bit): "Y'know, these drugs really do have side effects. But a lot of stuff does. And they do some people some good. Maybe if just the people who really need them take them, things will work themselves out."

This all should make Merck's path forward in their Vioxx lawsuits a little easier. They could still face a punitive-damages avalanche, of course, and a lot of lawyers will be working to get the snowpack loosened up. I assume that the first case will be tried in Mississippi, Texas, or some other jury award paradise - picking the right venue is part of the art.

I'm just glad that the "Toxic drugs! Film at eleven!" momentum has been lost. I think that the industry, the stock market, the public, and (most definitely) the press were really close to panic there for a bit. (Naturally enough, in the last case, since panic sells.) But outside of advertising revenue, it does no one any good. If you make the right decision in that frame of mind, it's generally by accident.

Comments (2) + TrackBacks (0) | Category: Cardiovascular Disease


COMMENTS

1. John Thacker on February 21, 2005 1:27 PM writes...

"I assume that the first case will be tried in Mississippi, Texas, or some other jury award paradise - picking the right venue is part of the art."

Possibly not. The recently passed and signed Class Action Fairness Act curtails venue shopping by quite a lot. Basically it removes to federal court class action lawsuits which consist of people in several states suing over behavior in several states. No longer can people forum shop by having one named member of the class being from the named state.

Permalink to Comment

2. John Wurzelmann on February 22, 2005 10:44 AM writes...

In a somewhat related aside, Why is it that the public or industry professionals have to pay for electronic access to advisory meetings such as just took place? It seems to me at the least that an audio feed, either live streaming or off-line format (MP3) should be available at the FDA or elsewhere. After all the FDA is supported by Tax payer money. Let's hear it for transparency in government. Perhaps the blogosphere, with its legendary political clout, can start a groundswell of enthusiasm for democratic reform of this public forum. I know transcripts will eventually be available, but I'd rather listen at my computer while otherwise multi-tasking.

John W

Permalink to Comment


EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
How Not to Do It: NMR Magnets
Allergan Escapes Valeant
Vytorin Actually Works
Fatalities at DuPont
The New York TImes on Drug Discovery
How Are Things at Princeton?
Phage-Derived Catalysts
Our Most Snorted-At Papers This Month. . .